Oct. 2022 – “We are interested in the use of this and related molecules to manage chronic pain in the clinic. Obviously, the interest is in using the compounds by themselves, given that they do not produce the sedation characteristic of dexmedetomidine, which is a great drug, but one that is largely limited to ICU situations where sedation is an advantage. Of particular interest is the possibility of combining the new ligands with low doses of opioids, producing at least additive, if not synergistic, analgesic effects without the adverse side effects typically associated with opioids.”
GIVING BACK IN STYLE – April 17, 2024 - “It’s still one day at…
RIDING THE WAVE...CALMLY – April 18, 2024 - “I was 13 years old and…
VIDEO – NEW YORK STORIES – April 23, 2024 - Sara Gettelfinger had steadily…
TRY IT, YOU’LL LIKE IT – April 18, 2024 - The rise in “sober…
AUDIO – SOBER MEN CAN DO THAT – April 4, 2024 - Acting icon…
I’LL BET HE GOES TO GA (not Georgia) – April 13, 2024 -The initial…